Free press releases distribution network?

Agency / Source: Sinclair & Co.

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!



Pharma CMOs Left Behind as Biosimilars Heat Up, New PharmSource Report Says - Pharma CMOs must provide value beyond capacity to secure contracts - PharmSource.com
Pharma CMOs Left Behind as Biosimilars Heat Up, New PharmSource Report Says

 

PRZOOM - /newswire/ - Raleigh, VA, United States, 2015/01/29 - Pharma CMOs must provide value beyond capacity to secure contracts - PharmSource.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

A new regulatory pathway has paved the way for the introduction of increasingly complex biosimilars in the United States, which has generated a great deal of excitement among pharmaceutical contract manufacturing organizations (CMOs) about possible new business opportunities.

In a new report from PharmSource, Catching a Wave: How Much Will CMOs Benefit from Biosimilars?, experts warn that such excitement is unwarranted and conclude that if CMOs hope to attract biosimilar business, they must provide meaningful value beyond mere manufacturing capacity.

Biosimilars are animal and human products that are “highly similar” to approved and licensed products that include vaccines, blood components and proteins. Biosimilars must have no clinically significant differences in terms of safety, purity or potency; differences are due to clinically inactive components.

Making extensive use of data, PharmSource researchers conducted an analysis of both commercialized biosimilars and biosimilars currently in development in the United States and Europe. The report assesses the degree to which CMOs that manufacture drug-substance or drug-product might benefit from the biosimilar boom.

The short answer to that question is not much, said Jim Miller, president of PharmSource and co-author of the report. PharmSource researchers found that financing and in-sourcing present significant challenges to CMOs seeking to move into the biosimilar space. CMOs that want to land biosimilar business must offer benefits or value beyond mere manufacturing capacity, he said.

“Biosimilars are not an especially big opportunity for CMOs because of the competitive dynamics of the end market for biosimilar products,” he said. “The challenge for CMOs today is to develop a strategy that enables them to participate more meaningfully when a third wave of biosimilar opportunities begin in 2020.”

The report includes data useful to CMOs and bio/pharmaceutical companies looking strategically at the outsourcing of drug manufacturing.

PharmSource (pharmsource.com) is the recognized unbiased authority of knowledge about the global bio/pharmaceutical contract services industry. The company’s proprietary publications, databases, research tools and analyses inform buyers and sellers of bio/pharma contract services about industry trends, activities and partnership opportunities.

Since 1996, CMOs, CDMOs and CROs worldwide have looked to PharmSource for critical information delivered with timeliness and integrity. Learn more at the PharmSource website.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Sinclair & Co.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Pharma CMOs Left Behind as Biosimilars Heat Up, New PharmSource Report Says

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
|
Contact: Karen Stinneford - Sinclair-Co.com 
919-833-9102 kys[.]sinclair-co.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Sinclair & Co. securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!




Read Latest Press Releases From Sinclair & Co. / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Press Releases:

Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (telotristat Ethyl)
BD Receives FDA 510(k) Clearance for New Immunological Diagnostic System
Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine
Somatuline® Autogel® 120 Mg Receives Japanese Approval for A New Indication for the Treatment of Gastro-entero-pancreatic Neuroendocrine Tumors
OTC Topical Drugs Market Size will Grow Profitably in the Near Future 2017-2025 Finds PMR
Bioinformatics Market Size to Expand at 20.4% CAGR through 2020 Reports Persistence Market Research
Australia Nitric Acid Market Expected to Reach at Value of $1.3B by 2024 End Says PMR
Commodity Chemicals Market Projected to be Resilient by 2020 Says Persistence Market Research
Cell Expansion Market Set to Garner Staggering Revenues by 2025 Reports PMR
Soft Tissue Sarcoma Treatment Market Revenue Predicted To Go Up by 2025 Finds Persistence Market Research

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...



PREMIUM Members


Visit  La Bella Bakery Artisan Bakery Arizona

Visit  Rapid Recovery

Visit  MagLar, Inc.







 
  ©2017 PRZOOM — Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today